Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry.
Dr. Ninad Deshpanday has been appointed President of Research and Development at CDMO Kemwell Biopharma.
With over 22 years of experience in the pharmaceutical business – both in the US and India – Dr. Deshpanday comes to Kemwell direct from Lupin, in Pune, India where he was President of Pharmaceutical R&D.
"Dr. Deshpanday brings a unique combination of leadership skills and technical expertise in pharmaceutical development, as well as excellent business development skills with a very strong network of customers in the US, Europe and Asia,” said Anurag Bagaria , Chairman and Managing Director of Kemwell.
Definiens, provider of solutions in image and data analysis for quantitative digital pathology, has appointed Dr. Ralf Huss as Chief Medical Officer.
The ex-Global Head of Histopathology and Tissue Biomarker at Roche Diagnostics has more than 20 years of training and experience in his field and is also the co-founder of the biotech company APCETH.
Definiens CEO Thomas Heydler welcomed the new appointment and added: “Professor Huss’ expertise will be invaluable in further strengthening Definiens’ leading role in quantitative digital pathology for life science research, tissue diagnostics development and clinical routine.”
Pari Kazeminy has been appointed as Business Development Manager at San Diego based company BioSurplus.
In her previous role, Kazeminy sold pre-clinical in vivo research models to the pharmaceutical, biotechnology and medical device industries as an Account Executive at Harlan.
BioSurplus’ CMO, Jackie Townsend welcomed her to the team saying Kazeminy’s years of experience in the Life Science Industry will “play a vital role” in providing the company’s “customer base with a range of options for liquidating and maximizing the value of their surplus assets.”
Physicians’ Capital Investment – a clinical and healthcare service company with over 100 years experienced – has announced the appointment of Adam Feldman to General Counsel.
Pedro Juan Vergne-Morell, CEO of PCI said: "With the addition of Adam's expertise and talent, PCI is positioned for unprecedented growth in the development of new medical facilities and we couldn't be happier."
In other news:
Richard A. Meir, as of March 1, will become Executive Vice President & Chief Financial Officer of medical equipment distributor Owens & Minor.
Indian Pharmaceutical Communications company Imprimus PR has appointed Gracelle Gerber to the position of CEO, following the release of former CEO Aman Gupta. Nymphia Vishin, formerly the Chief Strategy Analyst at Imprimis, will also become Deputy CEO of the firm in a bunch of other senior appointments.